Group 1: Key Points on Kede CNC - Kede CNC's core technology and component procurement do not involve U.S. origin goods, resulting in minimal impact from tariffs [1] - The company focuses on independent research and development of key functional components, achieving self-control over five-axis CNC systems, servo drives, and motors [1] - Orders are driven by both repurchases of old models and the expansion of new products, with a 13% increase in traditional five-axis vertical machining center orders and a 40% repurchase rate for machine tool products [1] - The five-axis horizontal machining centers and five-axis horizontal milling-turning composite machining centers have diverse specifications suitable for processing complex structural parts, significantly enhancing processing efficiency and precision [1] - The blade tip grinding products contribute to increasing the localization rate of aircraft engines, promoting the rapid and high-quality development of core technologies in the aviation industry [1] Group 2: Key Points on Novogene - Novogene's overseas conventional business revenue for 2024 has exceeded 100 million yuan, accounting for 7.4% of total revenue, with significant domestic client supply chain import substitution opportunities expected to drive growth [2] - Import enterprises hold over 50% market share in research and diagnostic clients, with even higher shares in pharmaceutical companies, indicating strong domestic replacement potential [2] - The domestic gross margin has declined due to intensified competition and product structure adjustments, although the sales proportion of new product categories is increasing, with some products maintaining good gross margins [2] - Novogene collaborates comprehensively with BGI in areas such as gene sequencing and D detection, with potential for deeper cooperation in Alzheimer's disease testing in the future [2]

华夏时报（www.chinatimes.net.cn）记者 夏高琴 南京报道 曾借新冠检测试剂实现业绩爆发的生物科技企业诺唯赞（688105.SH），正试图以"半价补贴"的策略抢占进口替代 市场。 4月10日起至4月30日，诺唯赞对新用户首次下单给予产品直降50%优惠。4月11日晚间诺唯赞披露的投资者关系活 动记录中，该司董事长、总经理曹林强调："在这一轮浪潮中，考虑到成本和供应链安全，客户国产替代的主动性 意愿会更强，在这样的外部大环境下，我们进行进口替代的势能大幅增长。" 此番表态背后，是实验室进口仪器设备及试剂耗材因关税导致采购成本及供应链稳定性大打折扣的现实的倒逼。 然而，回到企业本身，其最新披露的2024年年报也暴露多重隐忧。尽管诺唯赞2024年营收微增7.15%至13.78亿 元，其归母净利润仍亏损1809.38万元，经营活动现金流缺口扩大至968万元。在同行业可比企业研发投入普遍维 持增长的态势下，诺唯赞研发费用连续两年下滑，薪酬结构发生分化，高管团队薪酬大幅增加，部分高管薪酬同 比增长超90%，研发人员整体薪酬却在人数增长前提下不升反降。 全线产品降价50% "诺唯赞目前主要有几个客户群，包括 ...

诺唯赞 20250410 2025-04-11 摘要 • 诺唯赞 2024 年生命科学业务营收达 10.3 亿元，国内收入增长 12%，海 外收入激增 122%，整体增长 19%，生物试剂出货量增长超 50%，海外 市场毛利率高达 81%，仪器设备毛利率接近 90%。 • 生物医药业务营收 1.8 亿元，虽技术服务下滑 30%，但 GLP-1 商业化进 展显著，一季度销售额近 5,000 万元，与多家头部客户建立稳定关系，预 示未来增长潜力。 • 诊断业务销售额同比下降 30%至 1.66 亿元，主要因收缩常规 POCT 产品 线，集中资源于呼吸道及 AD 领域，与迈瑞合作落地呼吸道产品商业化， AD 领域完成取证及初步商业化。 • 公司 2024 年归母净利润亏损 1,800 万元，同比减亏 5,000 万元，扣除股 份支付影响后经营性净利润略微盈利，通过控制费用、聚焦研发核心项目 提升运营效率。 • 2024 年生命科学板块净利润约 1.8 亿元，诊断业务亏损 1.2 亿元，主要 因 AD 试剂和仪器研发投入，微流控业务因尚未商业化，研发投入近 6,000 万元。 诺唯赞在生命科学业务方面取得了哪些具体成 ...

Core Viewpoint - In 2024, Novogene achieved a revenue of 1.378 billion RMB, marking a year-on-year growth of 7.15%, while the net profit attributable to the parent company was a loss of 18.09 million RMB, which represents a reduction in losses by 52.86 million RMB compared to the previous year [1][2]. Financial Performance - The total revenue for 2024 was 1,377,898,264.65 RMB, up 7.15% from 1,285,988,243.93 RMB in 2023 [2]. - The net profit attributable to the parent company was -18,093,809.99 RMB, an improvement from -70,956,239.35 RMB in 2023 [2]. - The net profit after deducting non-recurring gains and losses was -83,215,469.70 RMB, compared to -192,739,350.74 RMB in the previous year, indicating a reduction in losses by 110 million RMB [2]. Cash Flow and Assets - The net cash flow from operating activities was -9,681,648.68 RMB, a significant decline of 106.33% from 152,987,968.81 RMB in 2023 [2]. - Total assets decreased by 12.14% to 5,048,663,079.32 RMB from 5,746,172,538.46 RMB in 2023 [2]. Executive Compensation - The total compensation for current and former directors, supervisors, and core technical personnel in 2024 was 10.6682 million RMB, an increase of 20.66% from 8.8418 million RMB in 2023 [2]. - The chairman and general manager, Cao Lin, received a salary of 1.3982 million RMB, reflecting a year-on-year increase of 91.56% [3]. - Other executives also saw significant salary increases, with the vice president Zhang Lijun's salary rising by 97.4% to 1.3291 million RMB [3].

Core Points - The company reported a revenue of 1.378 billion yuan for 2024, representing a year-on-year growth of 7.15% [1][3] - The net profit attributable to shareholders was -18.09 million yuan, an improvement from -70.96 million yuan in the previous year [1][3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -83.22 million yuan, compared to -192.74 million yuan in the previous year [1][3] - The net cash flow from operating activities was -9.68 million yuan, a significant decline from 152.99 million yuan in the previous year [1][3] - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares, totaling approximately 59.66 million yuan [1] Financial Data Summary - Revenue for 2024 was 1.378 billion yuan, up from 1.286 billion yuan in 2023, marking a 7.15% increase [3] - The net profit attributable to shareholders improved from -70.96 million yuan in 2023 to -18.09 million yuan in 2024 [3] - The net profit after excluding non-recurring items improved from -192.74 million yuan in 2023 to -83.22 million yuan in 2024 [3] - The net cash flow from operating activities decreased from 152.99 million yuan in 2023 to -9.68 million yuan in 2024, a decline of 106.33% [3] IPO and Fundraising Information - The company raised a total of 2.201 billion yuan from its initial public offering, with a net amount of 2.109 billion yuan after deducting issuance costs [4] - The final net fundraising amount exceeded the original plan by 907 million yuan [4] - The funds raised are intended for the establishment of a new headquarters and R&D base, expansion of the marketing network, and to supplement working capital [4]

（一）机构信息 1、基本信息 立信由我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市， 首席合伙人为朱建弟先生。立信是国际会计网络 BDO 的成员所，长期从事证券 服务业务，新《证券法》实施前具有证券、期货业务许可证，具有 H 股审计资 格，并已向美国公众公司会计监督委员会（PCAOB）注册登记。 南京诺唯赞生物科技股份有限公司董事会 2024 年度会计师事务所履职情况评估报告 南京诺唯赞生物科技股份有限公司（以下简称"公司"）聘请立信会计师事 务所（以下简称"立信"）作为公司 2024 年度财务报告审计机构及内部控制审 计机构。根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员 会颁布的《国有企业、上市公司选聘会计师事务所管理办法》，公司对立信 2024 年度审计过程中的履职情况进行评估。经评估，公司认为，立信在资质等方面合 规有效，履职能够保证独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所基本情况 2024 年度，立信为 693 家上市公司提供年报审计服务，审计收费总额 8.54 ...

前十大流通股东累计持有： 30466.95万股，累计占流通股比： 75.76%，较上期变化： 20224.90万股。 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 南京诺唯赞投资管理有限公司 | 16190.73 | 40.26 | 新进 | | 国寿成达(上海)健康产业股权投资中心(有限合伙) | 3095.80 | 7.70 | 不变 | | 杨奇 | 2187.29 | 5.44 | 不变 | | 曹林 | 2138.90 | 5.32 | 新进 | | 南京博英维创业投资合伙企业(有限合伙) | 1442.83 | 3.59 | 新进 | | 深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙企 业(有限合伙) | 1385.18 | 3.44 | -17.90 | | 南京唯赞创业投资合伙企业(有限合伙) | 1275.88 | 3.17 | 新进 | | 南京诺泰创业投资合伙企业(有限合伙) | 1184.83 | 2.95 | -54.50 | | 珠海广发信德敖东医药产业股权投资 ...

Core Viewpoint - BGI Genomics' stock closed at 51.92 yuan, down 2.55%, with a latest price-to-book ratio of 2.20 and a total market capitalization of 21.589 billion yuan [1] Financial Performance - For the third quarter of 2024, BGI Genomics reported revenue of 2.826 billion yuan, a year-on-year decrease of 10.10% [1] - The net profit for the same period was -124.166 million yuan, representing a year-on-year decline of 276.49% [1] - The gross profit margin stood at 45.22% [1] Market Activity - On April 3, 2024, BGI Genomics experienced a net outflow of main funds amounting to 22.093 million yuan, with a total outflow of 17.1172 million yuan over the past five days [1] Company Overview - BGI Genomics specializes in providing research services and precision medical testing solutions through multi-omics big data technologies, including gene testing, mass spectrometry, and bioinformatics analysis [1] - The company's main products include prenatal nutrition testing, human amino acid testing, and human vitamin testing [1] Awards and Recognition - BGI Genomics has received several awards, including "2022 ESG Best Social Responsibility Enterprise," "2023 Best Strategic Layout Enterprise for Medical Device Export," and "2022 Annual Investor Relations Gold Award Outstanding IR Company," enhancing its brand recognition and influence [1] Industry Comparison - BGI Genomics has a price-to-earnings (P/E) ratio of -212.46 (TTM) and 232.39 (static), with a market capitalization of 21.589 billion yuan [2] - The industry average P/E ratio is 46.48 (TTM) and 50.12 (static), with an average market capitalization of 107.65 billion yuan [2] - The industry median P/E ratio is 31.96 (TTM) and 31.10 (static), with a median market capitalization of 48.33 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights Berry Genomics' current market performance, including a recent stock price drop and its financial metrics such as market capitalization and price-to-book ratio [1] - As of January 10, 2025, Berry Genomics has 44,326 shareholders, a decrease of 711 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in gene testing services and related equipment and reagent sales, leveraging high-throughput sequencing technology [1] Group 2 - Berry Genomics has established a leadership position in genetics through its comprehensive "product + service" solutions for hospitals and medical laboratories, particularly with its NIPT project [1] - The company has developed proprietary cSMART liquid biopsy technology, which has received domestic and international patents, solidifying its leading position in oncology [1] - For the third quarter of 2024, Berry Genomics reported revenue of 823 million yuan, a year-on-year decrease of 4.96%, while net profit increased by 107.70% to 10.39 million yuan, with a gross margin of 50.61% [1] Group 3 - In terms of valuation metrics, Berry Genomics has a TTM PE ratio of -16.97 and a static PE ratio of -11.20, with a price-to-book ratio of 2.55 and a total market capitalization of 4.783 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 44.72 and static PE at 48.61, indicating that Berry Genomics is underperforming compared to its peers [2] - The industry median price-to-book ratio is 2.47, suggesting that Berry Genomics is relatively aligned with industry standards in terms of market valuation [2]

Group 1 - The overall profitability of the A-share market is weak, with cumulative net profit for non-financial companies down by 3.7% year-on-year, while operating revenue increased by 3.8% [6][15][12] - As of March 8, 2024, 1,066 listed companies have disclosed their performance reports, with 47% having previously issued earnings forecasts [6][12] - The performance of the CSI 500 index is superior, with a net profit growth of 8.7%, outperforming small-cap indices [15][16] Group 2 - The pharmaceutical and non-bank financial sectors are leading, with continuous acceleration in year-on-year growth [23][24] - In the upstream raw materials sector, oil, petrochemicals, and coal show strong performance, while non-ferrous metals experienced a slight decline in Q3 2024 but showed signs of recovery in Q4 2024 [23][24] - The TMT sector, particularly the electronics industry, continues to thrive due to AI-driven demand, with revenue and performance showing positive growth for four consecutive quarters [27][28] Group 3 - The banking and non-bank financial sectors have a high proportion of companies with both revenue and performance growth, indicating a favorable economic environment [36][39] - In the midstream manufacturing sector, all five industries reported negative net profit growth, with only basic chemicals and defense industries showing slight recovery [28][29] - The consumer goods sector, particularly pharmaceuticals and food and beverage, has shown significant growth, while textiles and retail remain weak [28][29] Group 4 - The expected net profit growth for the entire A-share market in 2025 is projected to be around 1.5%, with non-financial companies expected to see a 5% increase [23][24] - The performance of the component and aerospace equipment industries remains high, with significant improvements noted in the battery and military electronics sectors [42][46] - The overall performance of the main board and growth enterprise board is significantly better than that of the sci-tech innovation board and the northern stock exchange [15][16]